pipette
ESEspañol

Low-Intensity Focused Ultrasound of the Amygdala in Depression and Anxiety: A First-in-Human Active-Controlled Trial

A. R. Arulpragasam, M. van 't Wout-Frank, Y. A. Berlow, E. Aiken, A. Gorbatov, R. Van Patten, J. G. Gillotti, H. R. Swearingen, C. R. Faucher, H. Adams, N. C. R. McLaughlin, I. Liberzon, J. Barredo, S. Correia, B. Greenberg, N. S. Philip

PreprintClaims a big stepReal-world use

In the authors' words

BackgroundLow-intensity focused ultrasound (FUS) offers a noninvasive method for directly modulating deep brain structures with millimeter-scale precision, potentially addressing a major limitation of existing noninvasive neuromodulation approaches. The amygdala is a key node in affective neurocircuitry and a compelling target for psychiatric intervention. We conducted a first-in-human active controlled trial (NCT05147142) of amygdala-targeted FUS in patients with major depressive disorder, examining safety and target engagement. MethodsTen participants with major depressive disorder completed a single-blind randomized crossover trial with blinded symptom ratings, comparing imaging-guided FUS targeting the right amygdala versus left primary somatosensory cortex as an active control. FUS comprised two 10-minute applications within diagnostic ultrasound safety limits. Primary outcomes were safety and target engagement assessed with BOLD-fMRI during sonication, post-sonication arterial spin labeling (ASL) and resting-state functional connectivity. Secondary and exploratory outcomes included symptom change and imaging-symptom relationships. ResultsNine participants completed both sessions. No serious adverse events occurred; neurological, neuropsychological, and MRI safety assessments were unremarkable. Adverse events were more frequent after amygdala than control sonication (p=0.028); one participant experienced clinical worsening following amygdala sonication and required monitoring. Amygdala sonication produced greater perfusion change in the targeted amygdala compared to the control region (p<0.001), and ipsilateral hippocampus (p<0.001). BOLD-fMRI during sonication demonstrated engagement of ventromedial prefrontal and rostral anterior cingulate regions, while post-sonication resting-state connectivity decreased between basolateral amygdala and sensorimotor regions (corrected ps<0.05). Symptom improvement did not differ between conditions, but exploratory imaging-symptom relationships were significant. Spontaneous reports of calm, clarity, or lightness occurred after amygdala but not control sonication (p<0.001). ConclusionsAmygdala-targeted FUS produced anatomically specific, multimodal evidence of neuromodulation relative to active control, with a manageable safety profile. Convergent target and circuit-level signals support further development of FUS as a precision approach for modulating deep brain targets in psychiatric disorders.

Main resultLimitation the authors admit

In plain words AI summary

Researchers tested low-intensity focused ultrasound on the amygdala in ten people with major depressive disorder. They compared amygdala targeting to a control treatment on a different brain area in a single-blind randomized crossover trial. No serious adverse events occurred, though side effects were more common after amygdala treatment. Brain imaging showed the amygdala treatment changed blood flow in the targeted area and connected regions. Participants reported feeling calm, clarity, or lightness only after amygdala treatment, not after the control.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Monday, September 21. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.18.26363360